On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies

被引：39

作者：

Bruno, R. ^{[1
]}

Claret, L. ^{[1
]}

机构：

[1] Pharsight, Munich, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 86卷 / 02期

关键词：

CELL LUNG-CANCER; MODEL;

D O I：

10.1038/clpt.2009.97

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Drug-independent models that link biomarker response to clinical end points are critical to support early (end of phase II) clinical decisions. In oncology, change in tumor size (a biomarker of drug effect evaluated in phase II) is linked to survival (a phase II end point) in some solid tumors. Change in tumor size can be used as a primary end point in the design and evaluation of phase II studies and in supporting go/no-go decisions and phase II study design.

引用

收藏

页码：136 / 138

页数：4

相关论文

共 10 条

[1]

Claret L, 2006, J CLIN ONCOL, V24, p307S

[2]

CLARET L, 2008, PAGE, V17

[3]

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics [J].

Claret, Laurent ;

Girard, Pascal ;

Hoff, Paulo M. ;

Van Cutsem, Eric ;

Zuideveld, Klaas P. ;

Jorga, Karin ;

Fagerberg, Jan ;

Bruno, Rene .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4103-4108

[4]

Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer [J].

Karrison, Theodore G. ;

Maitland, Michael L. ;

Stadler, Walter M. ;

Ratain, Mark J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (19) :1455-1461

[5]

Can the pharmaceutical industry reduce attrition rates? [J].

Kola, I ;

Landis, J .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715

[6]

LAVIN PT, 1981, CANCER CLIN TRIALS, V4, P451

[7]

Recommended changes to oncology clinical trial design: Revolution or evolution? [J].

Ratain, Mark J. ;

Humphrey, Rachel W. ;

Gordon, Gary B. ;

Fyfe, Gwen ;

Adamson, Peter C. ;

Fleming, Thomas R. ;

Stadler, Walter M. ;

Berry, Donald A. ;

Peck, Carl C. .

EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) :8-11

[8]

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine plus carboplatin in non-small cell lung cancer patients [J].

Tham, Lai-San ;

Wang, Lingzhi ;

Soo, Ross A. ;

Lee, Soo-Chin ;

Lee, How-Sung ;

Yong, Wei-Peng ;

Goh, Boon-Cher ;

Holford, Nicholas H. G. .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4213-4218

[9]

*US FDA, 2008, GUID IND END OF PHAS

[10]

Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development [J].

Wang, Y. ;

Sung, C. ;

Dartois, C. ;

Ramchandani, R. ;

Booth, B. P. ;

Rock, E. ;

Gobburu, J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (02) :167-174